Physician profile
Amar Bansal
NPI 1710929716
$43,213.51
in general payments reported to CMS, 2019-2025
16 companies · $63.49 in 2025
The $63.49 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,288 · 2020: $2,234 · 2021: $184 · 2022: $2,099 · 2023: $448 · 2024: $29K · 2025: $63.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $3,063 · Travel and Lodging: $3,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,300.00 |
| Food and Beverage | $3,063.21 |
| Travel and Lodging | $3,045.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27,839.61 | 2024-2025 | Voquezna |
| Allergan, INC. | $10,590.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,532.00 | 2022-2024 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $521.57 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.25 | 2019-2022 | |
| Janssen Biotech, INC. | $338.66 | 2019-2024 | Stelara |
| Abbvie INC. | $320.89 | 2019-2024 | Rinvoq, Skyrizi |
| Mauna Kea Technologies, INC. | $176.89 | 2019-2024 | |
| Exact Sciences Corporation | $108.09 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $102.45 | 2019-2024 | |
| Csl Behring | $83.34 | 2019 | |
| Genzyme Corporation | $76.86 | 2024 | |
| Braintree Laboratories, INC. | $71.33 | 2019-2021 | |
| Endogastric Solutions, INC | $52.74 | 2021-2022 | |
| Gilead Sciences, INC. | $26.12 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.